Vivimed Labs
Vivimed Labs is a publicly listed Hyderabad-based pharmaceutical company operating four WHO/CGMP certified manufacturing facilities, providing contract manufacturing of formulations for global pharma majors (Novartis, Merck, Cipla, Pfizer, GSK, AstraZeneca, Teva, etc.) alongside APIs (via UQUIFA) and branded ophthalmic, nutraceutical and dermatology products for regulated and semi-regulated markets.
- Company typePublic
- Founded1991
- HeadquartersHyderabad, India
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Vivimed Labs does
Vivimed Labs Ltd. is a Hyderabad-based, publicly listed (BSE/NSE: 532660) pharmaceutical manufacturer founded in 1991. It operates four WHO GMP and CGMP certified manufacturing facilities across Jeedimetla (Hyderabad), Kashipur (Uttarakhand), and Haridwar, with additional certifications including PIC/S GMP, ISO 13485, CE for medical devices, ISO 9001/14001, and OHSAS 18001. The company runs three core business lines: contract manufacturing (CMO) of capsules, tablets, syrups, nasal sprays, and ointments for global pharmaceutical organizations; supply of niche molecule APIs (including via the UQUIFA business unit); and proprietary branded formulations in ophthalmic, nutraceutical, dermatology, and pain therapeutic segments with products such as Renicol, Lysicon-V, Care Tears, and Dexacort. Named contract manufacturing customers include Novartis (Otrivin), Merck (Nasivion), Cipla, Lupin, Dr. Reddy's, GSK, Pfizer, Gilead Sciences, AstraZeneca, and Teva, and the company serves semi-regulated markets (India, Southeast Asia, Africa, Middle East) while expanding into regulated markets in Europe, the US, Canada, and Australia. The business model is sales-led and B2B, combining professional-services-style contract manufacturing revenue with branded product sales, monetized through direct enterprise engagements without publicly disclosed pricing.
The company has a headcount of 550+ professionals across R&D and manufacturing units, with a contract research lab supporting its own MA and ANDA filings, and reportedly reached 30 market authorizations and ANDAs while expanding its MR field force from 40 to 100. Revenue is generated across multiple dosage platforms including solid orals, sterile products, nasal sprays, eye/ear drops, ointments, and medical devices. Financial trajectory has deteriorated sharply: Q3 FY2026 standalone sales fell 56.2% YoY to Rs 15.99 crore with a consolidated net loss of Rs 16.55 crore, and the company was admitted to India's Corporate Insolvency Resolution Process in April 2026. A Vivimed subsidiary, Vivimed Life Sciences, was part of a ~$15.26M US class action settlement over nitrosamine-contaminated valsartan/irbesartan/losartan, and the company has experienced multiple senior leadership exits including the CEO and CFO in October 2021 and the CFO in February 2024.
Vivimed Labs firmographics
Firmographics- Name
- Vivimed Labs
- Legal name
- Vivimed Labs Ltd.
- Website
- https://vivimedlabs.com
- Company type
- Public
- Founded year
- 1991
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- Vivimed Labs is a publicly listed Hyderabad-based pharmaceutical company operating four WHO/CGMP certified manufacturing facilities, providing contract manufacturing of formulations for global pharma majors (Novartis, Merck, Cipla, Pfizer, GSK, AstraZeneca, Teva, etc.) alongside APIs (via UQUIFA) and branded ophthalmic, nutraceutical and dermatology products for regulated and semi-regulated markets.
- Ownership category
- akta.pro rank
Vivimed Labs industry classification
Industry- Product category
- Pharmaceutical Manufacturing
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)
- akta.pro secondary industries
- Vitamins, Minerals & Supplements (VMS) (HLAIADAN), Clinical Quality Assurance (GCP QA, TMF/QMS oversight) (HLAGAKAI)
Keywords
Where Vivimed Labs is headquartered
LocationHeadquarters
- HQ city
- Hyderabad
- HQ country
- India
- HQ region
- Asia
Offices5 records
Markets served
Vivimed Labs business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Contract Manufacturing (CMO): Manufacturing pharmaceutical products for various reputed companies including capsules, tablets, syrups, nasal sprays, and ointments for India, Canada, and ROW markets
- Branded Formulations: Proprietary branded formulations in ophthalmic, nutraceuticals, dermatology, and pain management therapeutic segments
- Active Pharmaceutical Ingredients (APIs): Manufacturing and supply of niche molecules and APIs to pharmaceutical companies
Go-to-market motion1 record
Distribution channels1 record
Marketing channels1 record
Vivimed Labs product offering
Product offeringCore offering
Vivimed Labs manufactures and supplies active pharmaceutical ingredients (APIs) and finished dosage formulations (FDFs) across multiple delivery platforms including tablets, capsules, syrups, liquids, nasal sprays, ointments, and sterile products. The company operates four WHO and CGMP certified manufacturing facilities that produce contract-manufactured products for global pharmaceutical organizations (such as Novartis's Otrivin and Merck's Nasivion) as well as its own branded formulations in ophthalmic, nutraceutical, dermatology, and pain-management therapeutic segments.
Product overview
Vivimed Labs operates as a pharmaceutical company with a vertically integrated portfolio spanning active pharmaceutical ingredients (APIs) to finished dosage formulations and new drug delivery systems. The core offering centers on Finished Dosage Formulations, which encompasses four WHO-GMP certified manufacturing facilities producing capsules, tablets, syrups, liquids, sprays, and ointments across therapeutic categories including ophthalmic, nutraceuticals, and dermatology. The company serves both regulated markets (Europe, US, Canada, Australia) and semi-regulated markets (India, Southeast Asia, Africa, Middle East) through three main business models: contract manufacturing (CMO) for global pharmaceutical organizations, proprietary branded formulations, and R&D services supporting regulatory filings. Key manufactured products include Otrivin (for Novartis) and Nasivion (for Merck), while proprietary branded products include ophthalmic offerings like Renicol, Lysicon-V, Care Tears, and Dexacort, alongside nutraceutical and dermatology products.
Differentiator
Problem solved
Functional benefit
Brands
- UQUIFA: API (Active Pharmaceutical Ingredient) business unit of Vivimed Labs
- FDF (Finished Dosage Formulations)
Products and services
- Finished Dosage Formulations Comprehensive pharmaceutical formulation manufacturing across solid dosage forms (tablets, capsules), liquid orals, sprays, ointments, and specialized delivery platforms for regulated and semi-regulated markets, produced across four WHO and CGMP certified facilities.
- Contract Manufacturing (CMO) Contract manufacturing services for pharmaceutical formulations serving India, Canada and ROW markets, including production of capsules, tablets, syrups, nasal sprays, and ointments for various pharmaceutical companies (e.g., Novartis Otrivin, Merck Nasivion).
- Active Pharmaceutical Ingredients (APIs) Manufacturing and supply of niche molecules and Active Pharmaceutical Ingredients through the UQUIFA business unit, sold to pharmaceutical companies for use in formulations and finished dosage products.
- Branded Formulations - Ophthalmic Vivimed's proprietary ophthalmic product line including Renicol, Lysicon-V, Care Tears, and Dexacort, marketed as prescription and over-the-counter eye-care products in semi-regulated markets.
- Branded Formulations - Nutraceuticals and Dermatology Nutraceutical products including enzyme preparations, beta-lactams, antioxidants, and multi-vitamins targeted at women and children, together with dermatological products sold under the Vivimed brand.
- Otrivin (Contract Manufactured) Nasal decongestant spray manufactured at the Haridwar facility for Novartis as part of Vivimed's contract manufacturing operations.
- Nasivion (Contract Manufactured) Nasal drops and sprays including Nasivion and Nasivion Moist manufactured at the Haridwar facility for Merck under contract manufacturing agreements.
- R&D Services Research and development services supporting new drug delivery systems, ANDA filings, and market authorizations, including a contract research lab supporting regulatory submissions.
Quantifiable outcome
- Expanded MRs from 40 to 100 within short span
- +2 more outcomes
Companies that use Vivimed Labs
Customer profileNamed customers10 records
Segments3 records
Ideal customer profiles2 records
Vivimed Labs technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Vivimed Labs partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- NovartiscoreContract manufacturing relationship for Otrivin nasal spray products at the Haridwar facility
- MerckcoreContract manufacturing relationship for Nasivion nasal drops and Nasivion Moist spray at the Haridwar facility
- ActavisminorAcquisition of US FDA approved formulation manufacturing facility (2013) as referenced in press releases and acquisition call transcript
- UQUIFAminorAPI business investment by OrbiMed Asia as per investor disclosures
Scale indicators9 records
Recent moves9 records
Expansion highlights5 records
Vivimed Labs competitors and assessment
Company assessmentDirect peers
- Cipla: Indian global pharmaceutical manufacturer with overlapping presence in APIs, finished formulations, and contract manufacturing across ophthalmic, respiratory, and other therapeutic areas; a named CMO customer and direct competitor for global supply contracts.
- Lupin: Indian pharma major with extensive finished dosage manufacturing across multiple delivery platforms and a global CMO/CMIC presence; a named Vivimed customer and a comparable contract manufacturing and branded-generic player.
- Dr. Reddy's Laboratories: Integrated Indian pharmaceutical company operating in APIs, branded and generic formulations, and contract manufacturing; named Vivimed customer and a direct comparator in regulated-market generic expansion.
- Aurobindo Pharma: Large Indian pharmaceutical manufacturer with extensive API and finished dosage capabilities across sterile, oral, and injectable dosage forms; co-defendant with Vivimed in the US valsartan contamination litigation and a direct parallel in scale and product mix.
- Hetero Drugs: Indian vertically integrated pharma company with strong API and FDF operations including sterile injectables; co-defendant with Vivimed in the US nitrosamine class action and a direct comparator for contract manufacturing scale and regulatory track record.
- Strides Pharma: Indian pharma focused on finished dosage formulations, soft gels, and sterile injectables with a strong regulated-market presence; comparable as a mid-tier Indian FDF/CMO player expanding into the US, Europe, and Australia.
- Granules India: Indian manufacturer of APIs and finished dosages (tablets, capsules, oral solids) supplying regulated markets; comparable in vertically integrated API-to-FDF model and contract manufacturing customer base.
- Natco Pharma: Indian pharma with API manufacturing and finished formulations across oncology and other specialty therapeutic areas; comparable as a mid-cap Indian pharma with regulated-market ambitions and CMO exposure.
- Glenmark Pharmaceuticals: Indian research-driven pharmaceutical company with branded generics, APIs, and contract manufacturing across dermatology and other specialties; comparable for branded niche therapeutic portfolios and regulated-market supply.
Broad incumbents
- Zydus Lifesciences (Cadila Healthcare): Large integrated Indian pharmaceutical company spanning APIs, formulations, biologics, and consumer health; broader scale than Vivimed but operates in the same formulation manufacturing and contract development space across regulated and semi-regulated markets.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Vivimed Labs social profiles
Digital presenceVivimed Labs compliance and trust
Trust signalCompliance10 records
Vivimed Labs financial estimates
Financial estimateRevenue estimate
Valuation estimate
Vivimed Labs leadership team
Management profileNumber of profiles
Profiles2 records
Vivimed Labs subsidiaries and ownership
Company hierarchySubsidiaries1 record
Vivimed Labs funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Vivimed Labs M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Vivimed Labs
What does Vivimed Labs do?
Vivimed Labs manufactures and supplies active pharmaceutical ingredients (APIs) and finished dosage formulations (FDFs) across multiple delivery platforms including tablets, capsules, syrups, liquids, nasal sprays, ointments, and sterile products. The company operates four WHO and CGMP certified manufacturing facilities that produce contract-manufactured products for global pharmaceutical organizations (such as Novartis's Otrivin and Merck's Nasivion) as well as its own branded formulations in ophthalmic, nutraceutical, dermatology, and pain-management therapeutic segments.
Is Vivimed Labs a public or private company?
Vivimed Labs is a public company. It is classified as public and is currently operating.
When was Vivimed Labs founded?
Vivimed Labs was founded in 1991. It employs 501 to 1,000 people.
Where is Vivimed Labs based?
Vivimed Labs is headquartered in Hyderabad, India, in the Asia region.
How does Vivimed Labs make money?
Three revenue lines are on record. Contract Manufacturing (CMO) is the primary driver. The others are branded Formulations and active Pharmaceutical Ingredients (APIs).
Who are Vivimed Labs's main competitors?
Direct peers on record are Cipla, Lupin, Dr. Reddy's Laboratories, Aurobindo Pharma, Hetero Drugs, Strides Pharma, Granules India, Natco Pharma and Glenmark Pharmaceuticals. Zydus Lifesciences (Cadila Healthcare) is listed as a broad incumbent.
Does Vivimed Labs have an API?
No public API is recorded for Vivimed Labs.
What industry is Vivimed Labs in?
Vivimed Labs's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing, with a secondary code of HLAIADAN, Vitamins, Minerals & Supplements (VMS). Its NAICS code is 325412 and its SIC code is 2834.